Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3898 studies found for:    novartis
Show Display Options
Rank Status Study
21 Active, not recruiting Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: rMenB+OMV and MenACWY;   Biological: rMenB+OMV;   Biological: MenACWY
22 Active, not recruiting Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
Condition: Meningococcal Disease
Interventions: Biological: Meningoccal B recombinant vaccine together with routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age);   Biological: Routine vaccines: DTaP-IPV-Hib, HepB, PCV (2-4-6 months of age) and MMRV (12 months of age)
23 Completed
Has Results
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-Hib-IPV;   Biological: PCV;   Biological: MMR;   Biological: Hib
24 Recruiting Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Condition: ALK Positive Malignancies
Intervention: Drug: ceritinib
25 Completed
Has Results
Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ);   Biological: MenACWY-CRM conjugate vaccine;   Biological: Japanese Encephalitis vaccine
26 Completed
Has Results
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM + MMRV;   Biological: MMRV;   Biological: MenACWY-CRM
27 Completed
Has Results
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
Condition: Prevention of Meningococcal Disease
Interventions: Biological: MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation);   Biological: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation);   Biological: MenACWY PS (MenACWY-CRM, polysaccharide vaccine);   Biological: HBV (Hepatitis B vaccine);   Biological: Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197);   Biological: MMR (Measles, Mumps and Rubella vaccine);   Biological: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine);   Biological: Menjugate (Men C conjugated vaccine)
28 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Condition: Meningitis, Meningococcal
Interventions: Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: DTaP-IPV-HBV;   Biological: Hib;   Biological: Rotavirus;   Biological: Pneumococcal 7-valent Conjugate Vaccine;   Biological: HAV;   Biological: MMR-V;   Biological: DTaP
29 Completed
Has Results
Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Condition: Serogroup B Meningococcal Meningitis
Interventions: Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1);   Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2);   Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3);   Biological: Infanrix Hexa;   Biological: Menjugate;   Biological: Prevenar
30 Completed
Has Results
Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
Condition: Meningococcal Disease
Interventions: Biological: rMenB+OMV NZ;   Biological: Placebo
31 Completed
Has Results
Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
Condition: Meningococcal Disease
Interventions: Biological: 1a - rMenB+OMV NZ and routine vaccines;   Biological: 1b - rMenB+OMV NZ and routine vaccines;   Biological: 2a - Routine and rMenB+OMV NZ vaccines;   Biological: 2b - rMenB+OMV NZ and routine vaccines;   Biological: 3a - rMenB+OMV NZ and routine vaccines;   Biological: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations;   Biological: 4a- rMenB+OMV NZ and routine vaccines;   Biological: 4b - rMenB+OMV NZ and routine vaccines
32 Completed Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects
Condition: Meningococcal Disease
Intervention: Biological: rMenB+OMV
33 Completed
Has Results
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Conditions: Meningitis;   Meningococcal Infection
Interventions: Biological: MenACWY-CRM197;   Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine;   Biological: Hib (Haemophilus influenza b) Vaccine;   Biological: IPV (Inactivated Polio Vaccine) Vaccine;   Biological: Pneumococcal conjugate Vaccine;   Biological: MMR (Measles, Mumps, and Rubella) Vaccine;   Biological: Varicella Vaccine;   Biological: Hepatitis A Virus
34 Completed
Has Results
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: Novartis MenACWY-CRM;   Biological: Saline Placebo
35 Completed
Has Results
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.
Condition: Meningococcal Meningitis
Interventions: Biological: MenACWY-CRM conjugate vaccine, adjuvanted;   Biological: MenACWY polysaccharide vaccine;   Biological: MenACWY-CRM conjugate vaccine, unadjuvanted
36 Completed
Has Results
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Intervention: Biological: Recombinant meningococcal B + OMV NZ
37 Completed
Has Results
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Condition: Meningococcal Disease
Intervention: Biological: MenACWY-CRM
38 Completed
Has Results
A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.
Condition: Prevention of the Meningococcal Disease
Intervention: Biological: rMenB+OMV NZ
39 Completed Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers
Condition: Healthy
Intervention: Drug: Vildagliptin (LAF237)
40 Completed Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
Condition: Meningococcal Disease
Interventions: Biological: rMenB+OMV;   Other: Placebo;   Biological: Havrix Monodose Vaccine;   Biological: ABCWY

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years